SLN · NASDAQ
Silence Therapeutics (SLN) Stock Price & Fundamentals
Silence Therapeutics (SLN) closed at $506.11 on Oct 9, 2026, up 0.36% from the previous close of $504.28.
Share price, past year
1Y +43.95%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $506.11 |
| Sep 30, 2026 | $508.16 |
| Aug 31, 2026 | $500.96 |
| Jul 31, 2026 | $479.40 |
| Jun 30, 2026 | $464.77 |
| May 29, 2026 | $464.28 |
| Apr 30, 2026 | $427.36 |
| Mar 31, 2026 | $411.68 |
| Feb 27, 2026 | $389.32 |
| Jan 30, 2026 | $363.12 |
| Dec 31, 2025 | $343.36 |
| Nov 28, 2025 | $327.12 |
| Oct 31, 2025 | $336.33 |
Key statistics
- Market cap
- $71.74B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.44
- Revenue (TTM)
- $615.00K
- Net income (TTM)
- −$59.95M
- Shares outstanding
- 141.7M
- Dividend yield
- —
- 52-week range
- $320.76 – $519.20
Silence Therapeutics's market cap is $71.74B, based on a share price of $506.11 and 141.7M shares outstanding as of Jun 30, 2026.
Financials
Silence Therapeutics reported revenue of $559.00K for fiscal 2025, down 98.71% from fiscal 2024.
Silence Therapeutics reported a net loss of $88.61M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $559.00K | −98.7% | −$88.61M | −15,851.9% | −$0.63 | −$62.33M |
| FY2024ended Dec 31, 2024 | $43.26M | +36.7% | −$45.31M | −104.7% | −$0.33 | −$67.85M |
| FY2023ended Dec 31, 2023 | $31.64M | +46.1% | −$54.23M | −171.4% | −$0.49 | −$49.52M |
| FY2022ended Dec 31, 2022 | $21.66M | — | −$50.33M | −232.4% | −$0.52 | −$57.22M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$12.27M | −$0.09 |
| Q1 FY2026ended Mar 31, 2026 | $422.00K | −$14.96M | −$0.11 |
| Q4 FY2025ended Dec 31, 2025 | $34.00K | −$11.77M | −$0.09 |
| Q3 FY2025ended Sep 30, 2025 | $159.00K | −$20.96M | −$0.15 |
| Q2 FY2025ended Jun 30, 2025 | $224.00K | −$27.35M | −$0.19 |
| Q1 FY2025ended Mar 31, 2025 | $142.00K | −$28.53M | −$0.20 |
| Q4 FY2024ended Dec 31, 2024 | $25.31M | $12.30M | $0.08 |
| Q3 FY2024ended Sep 30, 2024 | $1.50M | −$35.54M | −$0.25 |
Company profile
- Name
- Silence Therapeutics plc
- Ticker
- SLN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 12 Hammersmith Grove, Office 205, London, W6 7AP
- Incorporated in
- X0
- SEC CIK
- 0001479615
Recent SEC filings
- Aug 12, 2026
- Aug 10, 2026
- Aug 10, 2026
- Aug 10, 2026
- Jun 23, 2026
- Jun 16, 2026
- Jun 11, 2026
- May 18, 2026
Frequently asked questions
What is Silence Therapeutics's stock price?
Silence Therapeutics (SLN) closed at $506.11 on Oct 9, 2026, up 0.36% from the previous close of $504.28.
What is Silence Therapeutics's market cap?
Silence Therapeutics's market cap is $71.74B, based on a share price of $506.11 and 141.7M shares outstanding as of Jun 30, 2026.
How much revenue does Silence Therapeutics make?
Silence Therapeutics reported revenue of $559.00K for fiscal 2025, down 98.71% from fiscal 2024.
Does Silence Therapeutics pay a dividend?
Silence Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Silence Therapeutics plc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures